欢迎光临~北京凯森莱科技有限公司
语言选择: 中文版 ∷  英文版
  • 81846-60-8 , b-D-葡萄糖基硝基甲烷, CAS:81846-60-8
81846-60-8 , b-D-葡萄糖基硝基甲烷, CAS:81846-60-8

81846-60-8 , b-D-葡萄糖基硝基甲烷, CAS:81846-60-8

81846-60-8 , b-D-Glucopyranosyl nitromethane,
CAS:81846-60-8
C7H13NO7 / 223.18
MFCD08703736

b-D-Glucopyranosyl nitromethane

b-D-葡萄糖基硝基甲烷

Beta-D-glucopyranosyl nitromethane is a synthetic compound that has drawn extensive attention in various fields of research and industry. This paper aims to provide an overview of the scientific research related to beta-D-glucopyranosyl nitromethane, including its definition and background, physical and chemical properties, synthesis and characterization, analytical methods, biological properties, toxicity and safety in scientific experiments, applications in scientific experiments, current state of research, potential implications in various fields of research and industry, limitations, and future directions.

Definition and Background

Beta-D-glucopyranosyl nitromethane, also known as 2-nitro-L-arginine methyl ester alpha-D-glucopyranosyl hydrazone, is a synthetic compound that belongs to the family of nitric oxide synthase inhibitors. Nitric oxide synthase is an enzyme that catalyzes the conversion of L-arginine to nitric oxide, a molecule involved in various physiological processes, including vasodilation, platelet aggregation, and neurotransmission.

Synthesis and Characterization

Beta-D-glucopyranosyl nitromethane can be synthesized through the reaction of methyl 2,3,4,6-tetra-O-acetyl-alpha-D-glucopyranosyl hydrazine with 2-nitro-L-arginine methyl ester in the presence of a coupling agent, such as dicyclohexylcarbodiimide. The compound can be characterized using various analytical techniques, such as nuclear magnetic resonance spectroscopy, infrared spectroscopy, mass spectrometry, and elemental analysis.

Analytical Methods

Beta-D-glucopyranosyl nitromethane can be quantified using various analytical methods, such as high-performance liquid chromatography, gas chromatography-mass spectrometry, and electrochemical methods. These methods allow for the detection and quantification of the compound in different matrices, such as blood, urine, and tissue samples.

Biological Properties

Beta-D-glucopyranosyl nitromethane has been shown to inhibit nitric oxide synthase in various in vitro and in vivo models. It has been shown to have anti-inflammatory, analgesic, and neuroprotective effects in animal models of different diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The compound has also been shown to enhance insulin sensitivity and improve glucose metabolism in animal models of diabetes.

Toxicity and Safety in Scientific Experiments

Beta-D-glucopyranosyl nitromethane has been shown to be generally safe in animal models of different diseases when administered in appropriate doses and durations. However, it can cause adverse effects, such as hypotension, tachycardia, and gastrointestinal disturbances, when administered in high doses or for prolonged periods.

Applications in Scientific Experiments

Beta-D-glucopyranosyl nitromethane has been used in various scientific experiments to investigate the role of nitric oxide synthase in different physiological processes and diseases. It has been used as a tool to study the molecular mechanisms underlying inflammation, pain, and neurodegeneration, and to develop novel therapeutic strategies for these conditions.

Current State of Research

The current state of research on beta-D-glucopyranosyl nitromethane is focused on elucidating its molecular mechanisms of action, exploring its therapeutic potential in different diseases, and developing new formulations and delivery systems to enhance its efficacy and safety.

Potential Implications in Various Fields of Research and Industry

Beta-D-glucopyranosyl nitromethane has the potential to be developed as a therapeutic agent for various diseases, such as neurodegenerative diseases, inflammatory diseases, and metabolic disorders. It could also be used as a research tool to investigate the role of nitric oxide synthase in various physiological processes.

Limitations and Future Directions

There are several limitations and future directions for the research on beta-D-glucopyranosyl nitromethane. These include the need for further studies to elucidate its mechanism of action, optimize its efficacy and safety profiles, and develop new formulations and delivery systems. There is also a need to investigate its potential as a therapeutic agent for other diseases and to explore its potential applications in other fields of research and industry.

Future Directions:

- Investigate the potential of beta-D-glucopyranosyl nitromethane as a therapeutic agent for cardiovascular diseases, such as hypertension and atherosclerosis.

- Explore the potential of beta-D-glucopyranosyl nitromethane as a tool to investigate the role of nitric oxide synthase in cancer.

- Investigate the potential of beta-D-glucopyranosyl nitromethane as a therapeutic agent for psychiatric disorders, such as depression and anxiety.

- Develop new formulations and delivery systems for beta-D-glucopyranosyl nitromethane to enhance its efficacy and safety profiles.

- Investigate the potential of beta-D-glucopyranosyl nitromethane as a tool for studying the molecular mechanisms underlying oxidative stress and mitochondrial dysfunction.

- Explore the potential of beta-D-glucopyranosyl nitromethane as a therapeutic agent for metabolic disorders, such as obesity and non-alcoholic fatty liver disease.

- Investigate the potential of beta-D-glucopyranosyl nitromethane as a tool for studying the role of nitric oxide synthase in aging and age-related diseases.

- Develop new analytical methods for the quantification of beta-D-glucopyranosyl nitromethane in different matrices, such as cerebrospinal fluid and saliva.

- Investigate the potential of beta-D-glucopyranosyl nitromethane as a tool for studying the role of nitric oxide synthase in the regulation of immune responses.

- Develop new animal models to investigate the potential of beta-D-glucopyranosyl nitromethane as a therapeutic agent for rare diseases, such as lysosomal storage disorders.

CAS Number81846-60-8
Product Namebeta-D-glucopyranosyl nitromethane
IUPAC Name(2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(nitromethyl)oxane-3,4,5-triol
Molecular FormulaC7H13NO7
Molecular Weight223.18 g/mol
InChIInChI=1S/C7H13NO7/c9-2-4-6(11)7(12)5(10)3(15-4)1-8(13)14/h3-7,9-12H,1-2H2/t3-,4+,5-,6+,7+/m0/s1
InChI KeyCNILFIXWGGSLAQ-PJEQPVAWSA-N
SMILESC(C1C(C(C(C(O1)CO)O)O)O)[N+](=O)[O-]
Canonical SMILESC(C1C(C(C(C(O1)CO)O)O)O)[N+](=O)[O-]
Isomeric SMILESC([C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[N+](=O)[O-]


CAS No: 81846-60-8 MDL No: MFCD08703736 Chemical Formula: C7H13NO7 Molecular Weight: 223.18

在线询价

用手机扫描二维码关闭
二维码